Immunohistochemistry analysis of checkpoint kinase 2 in oral squamous cell carcinoma
Appl. cancer res
;
40: 1-6, Oct. 19, 2020. ilus, tab
Article
Dans Anglais
| LILACS, Inca
| ID: biblio-1282611
ABSTRACT
Background:
Oral squamous cell carcinoma (OSCC) is the most frequently occurring malignant tumor of the head and neck region. Chk2 (Checkpoint kinase 2) is considered a tumor suppressor gene that acts on the cellular response to DNA damage. However, the role of Chk2 in OSCC prognosis is not yet fully understood. The objective of this study was to evaluate Chk2 immunoexpression in OSCC and to elucidate the association between its expression and clinicopathological parameters of prognostic importance, including overall survival, disease-free survival, and metastasis-free survival.Methods:
Chk2 expression was analyzed in 101 samples from patients with OSCC using immunohistochemistry. We stratified the patients into high expression (> 66% of cells positive for Chk2) and low expression (< 66%) groups.Results:
Chk2 showed high expression in 57.43% of OSCC. In our study, the expression of Chk2 did not correlate with any of the prognostic parameters evaluated. There was no difference between overall survival, metastasis-free survival, and disease-free survival according to Chk2 expression.Conclusion:
Despite the great importance of Chk2 in the development of different types of cancer, our findings do not favor Chk2 as a prognostic marker in oral squamous cell carcinoma.
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Sujet Principal:
Tumeurs de la bouche
/
Immunohistochimie
/
Carcinome épidermoïde
/
Checkpoint kinase 2
Type d'étude:
Étude pronostique
Limites du sujet:
Adulte
/
Femelle
/
Humains
/
Mâle
langue:
Anglais
Texte intégral:
Appl. cancer res
Thème du journal:
Tumeurs
Année:
2020
Type:
Article
Pays d'affiliation:
Brésil
Institution/Pays d'affiliation:
Department of Pathology and Forensic Medicine/BR
/
Department of Stomatology, Collective Health and Legal Dentistry/BR
/
Hematology Division, Department of Clinical Medicine/BR
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS